CD33 and acute myeloid leukemia: Taken together, conjugation of RBCEVs with anti‐CD33 antibody significantly promotes the delivery of miR‐125b ASO‐loaded RBCEVs thus enhancing the suppression of leukaemia in patient‐derived AML xenografts.